» Articles » PMID: 22282687

Emerging Antiplatelet Agents, Differential Pharmacology, and Clinical Utility

Overview
Journal J Blood Med
Publisher Dove Medical Press
Specialty Hematology
Date 2012 Jan 28
PMID 22282687
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The aspirin-clopidogrel combination is the current gold standard antiplatelet regimen following percutaneous coronary intervention and for the treatment of acute coronary syndrome. Despite the clinical benefit of this combination, patients continue to have vascular events. Another purinergic (P2Y(12)) receptor antagonist, prasugrel, became available last year. Although prasugrel is superior to clopidogrel in reducing clinical endpoints, a higher bleeding rate has been identified particularly in high-risk patients. Ticagrelor, a reversible P2Y(12) receptor antagonist currently being evaluated for approval, is also more potent than clopidogrel but has a similar bleeding risk. Two additional P2Y(12) antagonists are being investigated that will be available as an intravenous formulation. Apart from the P2Y(12) receptor antagonists, multiple other agents are being developed with unique mechanisms of platelet inhibition. These agents are being studied as an alternative to or in combination with clopidogrel. The antiplatelet agents currently under development include: thrombin receptor antagonists, phosphodiesterase inhibitors, a thromboxane-prostaglandin receptor antagonist, a serotonin receptor blocker, a platelet adhesion antagonist, nitric oxide-releasing aspirin, a glycoprotein VI antagonist, and a cyclooxygenase inhibitor. The purpose of this review is to describe the efficacy and safety profiles of the emerging antiplatelet agents and their role in the treatment of atherosclerotic cardiovascular diseases.

Citing Articles

Ticagrelor: An emerging oral antiplatelet agent.

Juneja S, Gupta K, Kaushal S J Pharmacol Pharmacother. 2013; 4(1):78-80.

PMID: 23662033 PMC: 3643352. DOI: 10.4103/0976-500X.107698.

References
1.
Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S . Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke. 2008; 39(6):1827-33. DOI: 10.1161/STROKEAHA.107.505131. View

2.
Jakubowski J, Payne C, Brandt J, Weerakkody G, Farid N, Small D . The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006; 47(3):377-84. DOI: 10.1097/01.fjc.0000210069.47205.c0. View

3.
Sabatine M, Cannon C, Gibson C, Lopez-Sendon J, Montalescot G, Theroux P . Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005; 294(10):1224-32. DOI: 10.1001/jama.294.10.1224. View

4.
Gurbel P, Bliden K, Butler K, Tantry U, Gesheff T, Wei C . Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120(25):2577-85. DOI: 10.1161/CIRCULATIONAHA.109.912550. View

5.
Gresele P, Migliacci R, Procacci A, De Monte P, Bonizzoni E . Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost. 2007; 97(3):444-50. View